| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bca3b113354c50e02fd69af5e5021250
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33b011e77b33662b8bf1f2ff2de7b661 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-31 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 |
| filingDate |
2018-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dae8e1b19b987b01e3f8905a8d29d37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4600162f2386ce4cb38fbeff57393cab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93e9160d7d8a474badab0a2e2387a17b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8024259c21204e13c5495e0721936ddc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_398fbb1cb3a234d4641407c462b5a586 |
| publicationDate |
2018-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018200144-A2 |
| titleOfInvention |
Synergistic combination of nucleic acid oligonucleotides and anthracycline chemotherapeutics |
| abstract |
The invention provides compositions and methods for treating cancers comprising administering a combination of antineoplastic agents, wherein the combination comprises anthracycline chemotherapeutics and one or more nucleic acid molecules capable of down-regulating expression of at least one splice variant of the IG20 gene, and wherein not all splice variants of the IG20 gene are down-regulated. In an embodiment, the splice variant of the IG20 gene is a MADD spiice variant and the nucleic acid molecules are siRNA, shRNA and antisense oligonucleotides which comprise a nucleic acid sequence complementary to a nucleic acid sequence of exon 13L of the MADD splice variant or to an mRNA transcript of exon 13L of the MADD splice variant. The invention encompasses methods of treating cancers which include combination therapy with nucleic acid molecules capable of down-regulating the expression of the at least one splice variant of the IG20 gene, and anthracycline chemotherapeutics. |
| priorityDate |
2017-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |